Castle Biosciences

139 articles with Castle Biosciences

• DecisionDx-Melanoma Test Independently Improved Identification of High-Risk Patients Compared to AJCC Staging in Stage I-II Cutaneous Melanoma

  4/23/2018

  Posters presented at the Real World Dermatology for Physician Assistants and Nurse Practitioners conference also include data demonstrating test’s clinical utility

• New Publication Highlights Significant Impact of DecisionDx-Melanoma Prognostic Test on Clinical Management of Patients with Melanoma

  4/4/2018

  Prospective, multicenter study recently published in SKIN The Journal of Cutaneous Medicine

• Independent Study Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-Melanoma Test Results on Patient Management Decisions in Melanoma

  3/21/2018

  New study of 91 patients with cutaneous melanoma is the third recent publication demonstrating that the DecisionDx-Melanoma test impacts one in two clinical management decisions.

• Castle Biosciences Announces Receipt of New York Laboratory Permit

  3/15/2018

  The receipt of the New York permit allows patients in that state to benefit from the Company’s DecisionDx®-Melanoma, DecisionDx®-UM and DecisionDx®-PRAME molecular diagnostic tests that provide actionable molecular information to inform patient care decisions.

• Two New Studies at the 2018 AAD Annual Meeting Highlight the Clinical Impact and Utilization of the DecisionDx-Melanoma Test for Cutaneous Melanoma

  2/16/2018

  The data will be presented during the 74th Annual Meeting of the American Academy of Dermatology (AAD), held in San Diego, CA from February 16-18.

• Castle Biosciences Release: DecisionDx-Melanoma Test for Cutaneous Melanoma Validated in Two Prospective Multicenter Study Cohorts to Provide Guidance for Sentinel Lymph Node Biopsy Recommendations

  2/16/2018

  Castle Biosciences announced the presentation of a study highlighting research on a new clinical use for the DecisionDx-Melanoma gene expression profile test to guide sentinel lymph node biopsy (SLNB) recommendations.

• Castle Biosciences Launches Next-Generation Sequencing Panel DecisionDx-UMSeq for Uveal Melanoma

  1/8/2018

  The new test will complement Castle Biosciences’ standard-of-care DecisionDx-UM gene expression profile (GEP) test that has been shown to be independent of and superior to mutational analysis in assessing likelihood of metastasis in UM.

• Castle Biosciences Announces the Appointment of Frank Stokes as Chief Financial Officer

  12/7/2017

  He joined Castle Biosciences effective December 4, 2017.

• Castle Biosciences Release: New Publication Highlights First Prospective Performance Assessment Of The Decisiondx-Melanoma Gene Expression Profile Test

  9/5/2017

• Castle Biosciences’ DecisionDx-Melanoma Test Performance Demonstrated In Newly Expanded Multicenter Cohort Of 782 Patients

  8/29/2017

• Castle Biosciences’ Uveal Melanoma Test Receives Positive Medicare Local Coverage Determination And Commercial Insurance Positive Coverage Policies

  7/18/2017

• Castle Biosciences Presents Three New Clinical Studies At ASCO 2017 Highlighting The Accuracy And Performance Of The Decisiondx-Melanoma Gene Expression Profile Test For Cutaneous Melanoma

  6/5/2017

• Castle Biosciences Release: Study Demonstrates Significant And Risk-Appropriate Clinical Impact Of DecisionDx-Melanoma Test Results On Patient Management Decisions

  5/15/2017

• Oxford Finance And Silicon Valley Bank Close $20 Million Credit Facility With Castle Biosciences

  5/11/2017

• Castle Biosciences’ Decisiondx-Melanoma Test Accurately Predicts Metastatic Risk In Patients With Head And Neck Melanoma

  5/1/2017

• Blue Cross Blue Shield Association Evidence Street Issues Positive Assessment Of Castle Biosciences’ Uveal Melanoma Gene Expression Test

  3/29/2017

• Castle Biosciences Release: Study Demonstrates That Decisiondx-Melanoma Test Improves Identification Of High Risk Skin Melanoma When Used With AJCC Outcome Prediction Tool

  1/23/2017

• Castle Biosciences Release: New Laboratory Receives Accreditation From College of American Pathologists

  1/17/2017

• Castle Biosciences Announces Launch Of New Eye Cancer Test To Measure Expression Of PRAME Gene

  10/10/2016

• Study Results With Castle Biosciences’ Uveal Melanoma Gene Expression Test Published In Journal Of Oncology

  8/10/2016